Beckman gains advantage in automated PSA (prostate specific antigen) testing
This article was originally published in Clinica
Executive Summary
Beckman Coulter's recent FDA approval of its automated free PSA test will give it a marketing advantage over Abbott Laboratories, leader in the automated total PSA testing market, as it becomes the first company to sell an automated version of both tests. It will also strengthen Beckman's competitive position with regard to its Access immunoassay system, according to analysts at Morgan Stanley Dean Witter.